Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D06BGO
|
|||
| Former ID |
DNCL002690
|
|||
| Drug Name |
Telcyta canfosfamide
|
|||
| Indication | Diffuse large B-cell lymphoma [ICD-11: 2A81; ICD-10: C83.3] | Phase 3 | [1] | |
| Mantle cell lymphoma [ICD-11: 2A85.5; ICD-10: C83.1] | Phase 3 | [1] | ||
| Non-hodgkin lymphoma [ICD-11: 2B33.5; ICD-10: C85.9] | Phase 3 | [1] | ||
| Company |
Telik
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Phase 3 randomised study of canfosfamide (Telcyta, TLK286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum-refractory or -resistant ovarian cancer.Eur J Cancer. 2009 Sep;45(13):2324-32. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.